You are here

Opdivo

Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO

Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO

BioSpace

Bristol Myers Squibb

PD-1 inhibitors

Flag link:

ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow

ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long shadow

Fierce Pharma

Bristol Myers Squibb

Flag link:

BMS, Halozyme score with subcutaneous version of Opdivo

BMS, Halozyme score with subcutaneous version of Opdivo

Fierce Pharma

Bristol Myers Squibb

clinical trials

Flag link:

Bristol Myers Squibb's Opdivo reign expands with new earlier-stage melanoma nod

Bristol Myers Squibb's Opdivo reign expands with new earlier-stage melanoma nod

Fierce Pharma

Bristol Myers Squibb

Flag link:

Latest trial win further supports expanded use of Bristol Myers’ Opdivo in lung cancer

Latest trial win further supports expanded use of Bristol Myers’ Opdivo in lung cancer

BioPharma Dive

Bristol Myers Squibb

non-small cell lung cancer

clinical trials

Flag link:

Bristol Myers gets positive opinion from CHMP for Opdivo

Bristol Myers gets positive opinion from CHMP for Opdivo

Pharmaceutical Business Review

Bristol Myers Squibb

Flag link:

Bristol Myers' Opdivo stages comeback in bladder cancer, teeing up 2 'Merck' showdowns

Bristol Myers' Opdivo stages comeback in bladder cancer, teeing up 2 'Merck' showdowns

Fierce Pharma

Bristol Myers Squibb

Flag link:

Sellas celebrates positive Phase I results in lung cancer

Sellas celebrates positive Phase I results in lung cancer

Clinical Trials Arena

clinical trials

Flag link:

ASCO: Seagen's top-selling drug under threat as Bristol Myers' Opdivo beats Adcetris in lymphoma

ASCO: Seagen's top-selling drug under threat as Bristol Myers' Opdivo beats Adcetris in lymphoma

Fierce Pharma

ASCO 2023 - Seagen

Bristol Myers Squibb

antibody-drug conjugate

Hodgkin's lymphoma

Flag link:

Bristol Myers accuses AstraZeneca of infringing patent on cancer blockbuster Opdivo—again

Bristol Myers accuses AstraZeneca of infringing patent on cancer blockbuster Opdivo—again

Fierce Pharma

Bristol Myers Squibb

Flag link:

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases

CP WIre

Bristol Myers Squibb

executive compensation

Flag link:

Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases

Bristol Myers Squibb

executive compensation

Flag link:

In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type

In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type

Fierce Pharma

Bristol Myers Squibb

pleural mseothelioma

clinical trials

Flag link:

Bristol Myers axes German launch of new cancer drug, citing pricing hurdles

Bristol Myers axes German launch of new cancer drug, citing pricing hurdles

Endpoints

Bristol Myers Squibb

Flag link:

Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’

Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’

BioPharma Dive

Bristol Myers Squibb

Flag link:

Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial

Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial

Seeking Alpha

Bristol Myers Squibb

platinum-resistant ovarian cancer

Flag link:

Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?

Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?

Endpoints

Bristol Myers Squibb

Flag link:

Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma

Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma

Fierce Pharma

Bristol Myers Squibb

Flag link:

ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?

ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?

Fierce Pharma

Bristol Myers Squibb

Flag link:

Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?

Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?

Fierce Pharma

Bristol Myers Squibb

Flag link:

Pages